TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network
4.8.2026 09:00:00 CEST | Business Wire | Press Release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/
Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services.
“As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Japan,” said Toru Suruga, executive officer and GM of technical engineering department at TOHKnet. “It demonstrates how live networks can evolve from today’s service requirements toward the next phase of digital infrastructure. Our relationship with Adtran has developed over many years through technical cooperation, trust and shared understanding. That foundation has enabled us to take an early and proactive role in advancing multi-PON coexistence in real network conditions. For us, it’s about building a more adaptable network for our customers while continuing to support the digital growth of the Tohoku region.”
The live trial used Adtran’s SDX 6400 Series, a high-capacity, software-defined OLT designed to support next-generation PON evolution within established fiber networks. The platform integrates 50G PON, XGS-PON and EPON capabilities on a single fiber, enabling TOHKnet to assess how 50G PON can be introduced alongside deployed access technologies without requiring major changes to the optical distribution network. Its modular architecture gives operators control over performance, scale and deployment timing, enabling upgrades to align with customer demand. For regional providers serving enterprise customers, this approach supports service continuity, efficient aggregation and long-term capacity planning as bandwidth requirements continue to expand.
“This demo represents an important step in the transition to higher-capacity broadband infrastructure,” commented Damian Deleard, head of APAC sales at Adtran. “What matters here is that 50G PON is being proven in the kind of environment operators actually run. Networks aren’t built from scratch each time a new technology arrives. They’re layered over years, supporting different systems and service needs. TOHKnet has shown real leadership in Japan by demonstrating how higher-capacity access can be achieved without disrupting existing services. Years of close collaboration have given us a shared understanding of practical network evolution: adding capacity while maintaining continuity and shaping upgrades around real customer needs.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the majority shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260803353435/en/
Contacts
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Rob Fink
+1 646 809 4048
investor.relations@adtran.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press Release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press Release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press Release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press Release
Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s
Bending Spoons has entered into a definitive agreement to acquire Airtable for $1.285 billion4.8.2026 08:30:00 CEST | Press Release
Bending Spoons S.p.A. (NASDAQ: BSP) announced that it has entered into a definitive agreement to acquire Airtable, in an all-cash transaction that values Airtable at an enterprise value of $1.285 billion, which, together with Airtable’s current net cash-and-cash-equivalents balance, implies an equity value of approximately $2.25 billion. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals. “We’re looking forward to welcoming Airtable into Bending Spoons,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Airtable is a pioneering brand reshaping how teams organize data and manage critical workflows. The value being delivered is reflected in annual recurring revenue growing over 20% YoY to approximately $480 million as of June 2026, and joining forces with Bending Spoons will accelerate innovation even further. We’re committed to investing in Airtable for the long run, and doubling down on its core strength: bringing teams and wor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom